alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['G719'],"[{'ncitCode': 'C66940', 'drugName': 'Afatinib'}]",[],LEVEL_1,LEVEL_Fda2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['23816960', '22452895', '25589191']",[],"Afatinib, a second-generation, irreversible tyrosine kinase inhibitor of EGFR, HER2, and HER4, is FDA-approved as first-line therapy in patients with non-small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 19 deletion or L858R, L861Q, G719, and/or S768I substitution mutations. FDA approval was based on the Phase II LUX-Lung 2 trial, which demonstrated an objective response rate of 61% in patients with EGFR mutant lung cancer treated with afatinib (PMID: 22452895). In the Phase III LUX-Lung 3 trial, afatinib significantly improved progression-free survival (PFS) in patients with EGFR mutant lung cancer compared to patients treated with chemotherapy comprised of cisplatin plus pemetrexed (13.6 months versus 6.9 months; hazard ratio=0.47; p=0.001) (PMID: 23816960). In a pooled analysis of the LUX-Lung 3 and 6 trials comparing overall survival in patients with EGFR mutation who were treated with afatinib versus those treated with chemotherapy, first-line treatment with afatinib significantly improved overall survival specifically in patients harboring exon 19 deletions compared to those treated with chemotherapy (31.7 versus 20.7 months; HR = 0.59; p = 0.0001) (PMID: 25589191)."
['Oncogenic Mutations'],"[{'ncitCode': 'C151967', 'drugName': 'Datopotamab Deruxtecan'}]",[],LEVEL_1,LEVEL_Fda2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['39761483', '39250535']",[],"Datopotamab deruxtecan (Dato-DXd) is an intravenously infused, TROP2-directed antibody drug conjugate that is FDA-approved for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. FDA approval is based on the results of the Phase II TROPION-Lung05 (NCT04484142) and Phase III TROPION-Lung01 (NCT04656652) trials of Dato-DXd in patients with previously treated EGFR-mutated NSCLC.
In the Phase II TROPION-Lung05 (NCT04484142) trial of Dato-DXd in patients with NSCLC harboring actionable alterations progressing on or after targeted therapy and platinum-based chemotherapy, patients with EGFR-mutated NSCLC (n=78 [exon 19 deletion: 41 (29.9%); exon 20 T790M: 26 (19.0%); exon 21 L858R: 25 (18.2%); exon 18 G719: 5 (3.6%); exon 21 L861Q: 3 (2.2%); exon 20 insertion: 2 (1.5%)]) demonstrated an overall response rate (ORR) of 43.6% (95% CI=32.4-55.3), with a 5.1% (n=4) complete response (CR) rate, 38.5% (n=30) partial response (PR) rate and 34.6% (n=27) stable disease (SD) rate, a disease control rate (DCR) of 82.1% (95% CI=71.7-89.8), a median duration of response (DOR) of 7.0 months (95% CI=4.2-10.2) and a median progression-free survival (PFS) of 5.8 months (95% CI=5.4-8.3) (PMID: 39761483).
In the Phase III TROPION-Lung01 (NCT04656652) trial of Dato-DXd versus docetaxel in patients with pretreated NSCLC, patients treated with Dato-DXd (n=299 [EGFR mutations: 39 (13.0%)]) demonstrated an ORR of 26.4% (95% CI= 21.5-31.8), with a 1.3% (n=4) CR rate, 25.1% (n=75) PR rate and 49.8% (n=149) SD rate, a DCR of 77.3% (95% CI=72.1-81.9), a median DOR of 7.1 months (95% CI=5.6-10.9), a median PFS of 4.4 months (95% CI=4.2-5.6) and a median overall survival (OS) of 12.9 months (95% CI=11.0-13.9) (PMID: 39250535). Patients treated with docetaxel (n=305 [EGFR mutations: 45 (14.8%)]) demonstrated an ORR of 12.8% (95% CI=9.3-17.1), with a 12.8% (n=39) PR rate and 50.2% (n=153) SD rate, a DCR of 64.9% (95% CI=59.3-70.3), a median DOR of 5.6 months (95% CI=5.4-8.1), a median PFS of 3.7 months (95% CI=2.9-4.2) (HR=0.75 [95% CI=0.62-0.91]; p=.004) and a median OS of 11.8 months (95% CI=10.1-12.8) (HR=0.94 [95% CI=0.78-1.14]; p=0.530) (PMID: 39250535)."
['G719'],"[{'ncitCode': 'C124993', 'drugName': 'Amivantamab'}, {'ncitCode': 'C15632', 'drugName': 'Chemotherapy'}]",[],LEVEL_2,LEVEL_Fda2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['37879444'],[],"Amivantamab is an intravenously infused, EGFR-MET bispecific monoclonal antibody that is FDA-approved for the treatment of adult patients in combination with carboplatin and pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations as detected by an FDA-approved test. Amivantamab plus chemotherapy is also recommended in the NCCN NSCLC Guidelines (v5.2024) as a ""Molecular And Biomarker-Directed Therapy For Advanced Or Metastatic Disease, Subsequent therapy"" treatment option for patients with EGFR S768I, L861Q and/or G719X-mutation-positive NSCLC. NCCN recommendation is based on the results of the Phase III MARIPOSA-2 (NCT04988295) trial of amivantamab plus chemotherapy versus chemotherapy in 394 patients with EGFR L858R and exon 19 deletion-mutant NSCLC. Note that the NCCN recommendation is based on clinical trial data that does not include patients with EGFR G719X-mutant NSCLC. In the Phase III MARIPOSA-2 (NCT04988295) trial, the amivantamab plus chemotherapy cohort (n=131 [n=89, exon 19 deletion; n=42, L858R]) demonstrated an overall response rate (ORR) of 64% (95% CI=55-72), a median progression-free survival (PFS) of 6.3 months (95% CI=5.6-8.4) and a median duration of response (DOR) of 6.9 months (95% CI=5.5-NE) while the chemotherapy cohort (n=263 [n=183, exon 19 deletion; n=79, L858R]) demonstrated an ORR of 36% (95% CI=30-42), a median PFS of 4.2 months (95% CI=4.0-4.4) and a median DOR of 5.6 months (95% CI=4.2-9.6) (PMID: 37879444)."
['G719'],"[{'ncitCode': 'C53398', 'drugName': 'Dacomitinib'}]",[],LEVEL_2,LEVEL_Fda2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['35770100'],[],"Dacomitinib is an orally available, small-molecule EGFR inhibitor that is FDA-approved for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations, as detected by an FDA-approved test. Dacomitinib is also recommended in the NCCN NSCLC Guidelines (v5.2024) as a ""Molecular And Biomarker-Directed Therapy For Advanced Or Metastatic Disease, First-line therapy"" treatment option for patients with EGFR S768I, L861Q and/or G719X-mutation-positive NSCLC. NCCN recommendation is based on the results of the Phase III ARCHER 1050 (NCT01774721) trial of dacomitinib versus erlotinib in 452 patients with EGFR L858R and exon 19 deletion-mutant NSCLC. Note that the NCCN recommendation is based on clinical trial data that does not include patients with EGFR G719X-mutant NSCLC. This recommendation is supported by data from a clinical study of dacomitinib in 32 patients with EGFR S768I, L861Q and/or G719X-mutant NSCLC (n=24, G719X; n=7, L861Q; n= 8, S768I). In this clinical study of dacomitinib, the overall cohort achieved 18 (56.3%) partial responses, a median progression-free survival of 10.3 months (95% CI=6.1-14.5) and the EGFR G719X-mutant subgroup demonstrated an overall response rate of 56.5% (PMID: 35770100)."
['G719'],"[{'ncitCode': 'C116377', 'drugName': 'Osimertinib'}]",[],LEVEL_2,LEVEL_Fda2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['37991747', '31825714']",[],"Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI) that inhibits T790M-mutant EGFR, is FDA-approved for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, and for patients with EGFR T790M-mutant NSCLC who have progressed on other EGFR TKIs. The NCCN lists osimertinib as a preferred regimen for EGFR G719-mutant NSCLC. In a phase II study of olaparib in patients with histologically confirmed metastatic or recurrent NSCLC harboring uncommon EGFR mutations, ten of nineteen patients with G719 mutations had a response for a mutant-specific overall response rate of 53% (PMID: 31825714). In the Phase II UNICORN trial of osimertinib in patients with previously untreated NSCLC harboring uncommon EGFR mutations, patients with EGFR G719-mutant NSCLC (n=20) demonstrated a response rate of 45% (90% CI=25.8, 65.8), a median progression-free survival of 5.1 months (95% CI=3.0, 9.7) and did not reach a median overall survival rate (95% CI=19.2, NR) (PMID: 37991747)."
['G719'],"[{'ncitCode': 'C65530', 'drugName': 'Erlotinib'}]",[],LEVEL_2,LEVEL_Fda2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['25668120'],[],"Erlotinib is an orally available, small molecule EGFR tyrosine kinase inhibitor that is FDA-approved as a single agent or in combination with ramucirumab for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 (L858R) mutations, as detected by an FDA-approved test. Erlotinib is also recommended in the NCCN NSCLC Guidelines (v5.2024) as a ""Molecular And Biomarker-Directed Therapy For Advanced Or Metastatic Disease, First-line therapy"" treatment option for patients with EGFR S768I, L861Q and/or G719X-mutation-positive NSCLC. NCCN recommendation is based on the results of the Phase III EURTAC (NCT00446225) trial of erlotinib versus chemotherapy in 173 patients with EGFR L858R and exon 19 deletion-mutant NSCLC. Note that the NCCN recommendation is based on clinical trial data that does not include patients with EGFR G719X-mutant NSCLC. This recommendation is supported by data from a clinical study of erlotinib and gefitinib monotherapies in 161 patients with EGFR S768I, L861Q and/or G719X-mutant lung adenocarcinoma (n=34, erlotinib cohort; n=127, gefitinib cohort) (n=78, G719X; n=57, L861Q; n= 7, S768I; n=9, G719X + L861Q; n=10, G719X + S768I). In this clinical study of erlotinib and gefitinib, the overall cohort demonstrated an overall response rate of 41.6%, with 64 patients achieving partial response (PR) (n=28, G719X; n=21, L861Q; n= 2, S768I; n=8, G719X + L861Q; n=5, G719X + S768I), 54 patients achieving stable disease (SD) (n=27, G719X; n=19, L861Q; n= 2, S768I; n=1, G719X + L861Q; n=5, G719X + S768I), and a median progression-free survival of 7.7 months (PMID: 25668120)."
['G719'],"[{'ncitCode': 'C1855', 'drugName': 'Gefitinib'}]",[],LEVEL_2,LEVEL_Fda2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['25668120'],[],"Gefitinib is an orally available, small molecule EGFR tyrosine kinase inhibitor that is FDA-approved as first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. Gefitinib is also recommended in the NCCN NSCLC Guidelines (v5.2024) as a ""Molecular And Biomarker-Directed Therapy For Advanced Or Metastatic Disease, First-line therapy"" treatment option for patients with EGFR S768I, L861Q and/or G719X-mutation-positive NSCLC. NCCN recommendation is based on the results of the Phase III IPASS (NCT00322452) trial of gefitinib versus chemotherapy in 261 patients with EGFR L858R and exon 19 deletion-mutant NSCLC. Note that the NCCN recommendation is based on clinical trial data that does not include patients with EGFR G719X-mutant NSCLC. This recommendation is supported by data from a clinical study of erlotinib and gefitinib monotherapies in 161 patients with EGFR S768I, L861Q and/or G719X-mutant lung adenocarcinoma (n=34, erlotinib cohort; n=127, gefitinib cohort) (n=78, G719X; n=57, L861Q; n= 7, S768I; n=9, G719X + L861Q; n=10, G719X + S768I). In this clinical study of erlotinib and gefitinib, the overall cohort demonstrated an overall response rate of 41.6%, with 64 patients achieving partial response (PR) (n=28, G719X; n=21, L861Q; n= 2, S768I; n=8, G719X + L861Q; n=5, G719X + S768I), 54 patients achieving stable disease (SD) (n=27, G719X; n=19, L861Q; n= 2, S768I; n=1, G719X + L861Q; n=5, G719X + S768I), and a median progression-free survival of 7.7 months (PMID: 25668120)."
"['L861Q', 'Exon 19 in-frame deletions', 'Exon 19 in-frame insertions', 'L858R', 'S768I', 'G719']","[{'ncitCode': 'C136987', 'drugName': 'Patritumab Deruxtecan'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['37689979', '38369013', '31661465', '34548309', '30057690', '34084213']",[],"Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate consisting of a HER3 antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. HER3 is the preferred heterodimeric partner for EGFR (PMID: 34084213, 30057690). In a phase I dose-escalation/expansion study (NCT03260491) of HER3-DXd in 57 patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) (n=33 with Exon 19 deletion), the objective response rate (ORR) was 39% (95% CI=26.0–52.4) and median progression-free survival (PFS) was 8.2 (95% CI=4.4–8.3) months (PMID: 34548309). In the phase II HERTHENA-Lung01 trial of HER3-DXd in 225 patients with previously treated EGFR-mutated NSCLC, the median PFS was 5.5 months (95% CI=5.1-5.9) and an objective response was observed in 67 patients (29.8%; 95% CI=23.9-36.2), with complete response observed in one patient (PMID: 37689979). In preclinical studies, in vitro and in vivo models containing HER3-expressing CM-3 cancer cells treated with U3-1402 (HER3-DXd) exhibited reduced cell viability and tumor volume, respectively (PMID: 31661465). In the Phase I U31402-A-U102 (NCT03260491) trial of HER3-DXd in 97 patients with EGFR-mutated NSCLC who had received prior EGFR tyrosine kinase inhibitor therapy and platinum-based chemotherapy (n=64, exon 19 deletion; n=29, L858R; n=4, G719A; n=2, L861Q; n=1, exon 19 insertion), the cohort demonstrated an ORR of 39.2% (n=38) (95% CI=29.4-49.6), with a 1% (n=1) confirmed response rate, 38.1% (n=37) partial response rate, 40.2% (n=39) stable disease rate and 12.4% (n=12) progressive disease rate, a median duration of response of 9.6 months (95% CI=6.9-15.4), a median PFS of 6.4 months (95% CI=4.9-8.3) and a median overall survival of 15.8 months (95% CI=10.8-21.5) (PMID: 38369013)."
['G719'],"[{'ncitCode': 'C124993', 'drugName': 'Amivantamab'}, {'ncitCode': 'C148147', 'drugName': 'Lazertinib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],[],"[{'link': 'https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516', 'abstract': 'Cho et al. Abstract #8516, ASCO 2024.'}]","Amivantamab is an intravenously infused, EGFR-MET bispecific monoclonal antibody that is FDA-approved for the treatment of adult patients in combination with carboplatin and pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations as detected by an FDA-approved test. There are promising clinical data in patients with EGFR S768I, L861Q and/or G719X-mutant NSCLC treated with amivantamab in combination with the third-generation EGFR tyrosine kinase inhibitor lazertinib. In the Phase I CHRYSALIS-2 (NCT04077463) trial of amivantamab plus lazertinib in 105 patients with atypical EGFR-mutated advanced NSCLC (54%, G719X; 24%, L861Q; 22%, S768I), the objective response rate (ORR) was 51% (95% CI=41-61) in the overall cohort, 54% in the EGFR G719X-mutant cohort (n=13) and 41% in the compound atypical EGFR-mutant cohort (n=17) (Abstract: Cho et al. Abstract #8516, ASCO 2024. https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516). Of the treatment-naive patients (n=49), the ORR was 55% (95% CI=40-69), the median progression-free survival was 19.5 months (95% CI=11.0-NE) and the median duration of response was not evaluable (95% CI=2.8-NE) (Abstract: Cho et al. Abstract #8516, ASCO 2024. https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)."
